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Splenic Marginal Zone Lymphoma in 5 Dogs (2001 –2008)
D. Stefanello, P. Valenti, E. Zini, S. Comazzi, M.E. Gelain, P. Roccabianca, G. Avallone,
M. Caniatti, and L. Marconato
Background: Splenic marginal zone lymphomas (MZL) in dogs arise from the marginal zone of B-cell follicles and can
progress slowly.
Objectives: To describe clinical features, treatment, and outcome of dogs with splenic MZL.
Animals: Five dogs with naturally occurring MZL.
Methods: Clinical, laboratory, and follow-up data were retrospectively reviewed. Diagnosis was based on clinical, histo-
pathological, and immunophenotypic features.
Results: All dogs had stage IV disease; among them, 2 were symptomatic (substage ‘‘b’’) because of splenic rupture. Four
dogs underwent splenectomy and adjuvant doxorubicin, and 1 dog underwent surgery only. Three out of the 4 dogs treated with
surgery and chemotherapy died of causes unrelated to lymphoma, after 760, 939, and 1,825 days, whereas the remaining dog
was alive and in complete remission after 445 days. The dog not receiving any adjuvant treatment had recurrence of the tumor
after 180 days.
Conclusions and Clinical Importance: Splenic MZL appears indolent and can beneﬁt from splenectomy, with or without
systemic chemotherapy.
Key words: Canine; Indolent lymphoma; Spleen.
The marginal zone is an anatomically distinct B-cellcompartment surrounding the lymphocytic corona
of the mantle zone in lymph node(s) (LNs), spleen, and
mucosa-associated lymphoid tissues (MALT).1 Lympho-
mas arising from this particular location within
lymphoid follicles are named marginal zone lymphoma
(MZL).
The World Health Organization (WHO) histological
classiﬁcation (2008) further divided human MZL into 3
subtypes, including that of MALT, spleen, and LNs2; the
clinical course is different for each of them. The WHO
classiﬁcation of hematopoietic and lymphoid tumors
of domestic animals has also divided them into sub-
types.1,3,4 Because of the limited number of reported
splenic MZL cases, a precise recommendation for ther-
apy is not yet available. The goal of this report was to
describe clinical features, treatment, and outcome of
dogs with splenic MZL.
Materials and Methods
Criteria for Selection of Cases
Medical records were reviewed to identify dogs with a histological
diagnosis of MZL presented to the authors’ institutions between 2001
and 2008. To be enrolled in the study, a complete staging work-up had
to be available, including signalment, history, presence or absence of
clinical signs, hematological proﬁle, calcemia, thoracic radiographs,
abdominal ultrasound, cytology and immunophenotype of enlarged
LN(s), spleen or liver, cytological and immunophenotypical bone
marrow (BM) evaluation, with or without histopathological examin-
ation of the involved tissue(s). Clonality assessment was performed on
spleen samples to conﬁrm the neoplastic origin of the disease.
Data pertaining to number and type of therapies given, response,
and outcome were retrieved.
Morphologic Features and Immunophenotype
Histological slides, including sections used for immunopheno-
typing, were reviewed to conﬁrm the diagnosis. The diagnosis was
made according to WHO histological classiﬁcation.3–5 Immuno-
phenotyping had to demonstrate the B-cell nature of neoplastic
lymphocytes.
Polymerase chain reaction (PCR) for antigen receptor rearrange-
ment (PARR) was performed on formalin ﬁxed-parafﬁn embedded
samples. DNA was isolated with a commercially available kit in ac-
cordance with the manufacturer’s protocol.a Nucleic acid was
spectrophotometrically measured with anND-100 Spectrophotometerb
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and PCR for GAPDH sequences was performed to evaluate the
presence of ampliﬁable DNA. Ampliﬁcation of immunoglobulin se-
quence was performed as already described.6
Treatment and Response Assessment
Treatment was provided by the attending clinician and was not
standardized. Dogs were treated according to disease stage and
location with therapeutic options being available at the time of
diagnosis.
Outcome was recorded for each included case. Complete remis-
sion (CR) was deﬁned as no clinical evidence of lymphoma. Partial
remission (PR) was deﬁned as 50% or greater decrease in one di-
mension of measurable tumor. Stable disease was deﬁned as less
than a 50% decrease in 1 dimension but no more than a 10% in-
crease in any dimension of all measurable tumors. Progressive
disease (PD) was deﬁned as a 10% or more increase in any dimen-
sion of measurable tumor. Relapse was deﬁned as clinical
reappearance and cytological evidence of lymphoma in any ana-
tomical site in dogs that have had CR, whereas relapse for animals
with PR was deﬁned as progression. Responses lasting o21 days
were considered as PD.
To evaluate response, reevaluation was conducted at the end of
the adopted therapy, and monthly thereafter until relapse. All en-
rolled dogs were monitored by the same clinician.
Results
Dogs
Nine client-owned dogs with splenic MZL were iden-
tiﬁed as potential cases for inclusion in the study.
However, among them, only 5 had an available histo-
pathological diagnosis of MZL and were enrolled. The
other 4 had a cytological diagnosis of medium macronu-
cleated cell (MMC) and were therefore not included in
the study.
Of the 5 dogs enrolled, 2 were pure-bred, 3 were mixed-
bred. There were 4 males (3 intact, 1 castrated) and 1
spayed female. Median age was 8 years (range, 7–10
years) and median weight was 10 kg (range, 8.0–29.0 kg).
All dogs had stage IV disease. Two dogs had signs related
to hemoabdomen (‘‘b’’ substage).
All dogs were treatment-naı¨ve at time of diagnosis.
Anemia (hematocrit o35%) was observed in 2 dogs
and none was hypercalcemic (Ca21 4 12mg/dL). Two
dogs had hemoabdomen because of splenic rupture. An
abdominal mass was palpated during routine examina-
tion in the remaining 3 dogs. In all dogs a focal, well
demarcated, hypoechoic mass was delineated in the
spleen on ultrasonographic examination. In all dogs,
both cytology and histology were available. Impression
smears of the spleen were obtained after splenectomy,
and cytology was consistent with a MMC diagnosis in all
of them. Histological samples were diagnosed as MZL
lymphomas, being characterized by focally extensive
nodular splenic lesions often surrounded by hemorrhage
or areas of severe extramedullary hematopoiesis (Figs
1–4). Splenic neoplastic nodules examined in early cases
were composed of the characteristic lighter stained broad
and continuous cuff of cells around small foci of darkly
stained residual small cells of mantle cell cuff with col-
lapsed germinal centers. In more advanced cases, the
multinodular pattern persisted but mantle cells were lost
and nodules tended to coalesce. Neoplastic cells were
monomorphic, with variably evident cell boundaries, an
abundant lightly eosinophilic cytoplasm, and round, 10–
14 mm nuclei with 1 distinct nucleolus. Mitoses were rare
to absent in all cases. Cells expressed consistently CD79-
aplha and CD20 and were CD3-epsilon negative.
B-cell clonality was detected in 3 splenic cases. In 2
cases, formalin-ﬁxed parafﬁn embedded tissue yielded
very low DNA amounts, thereby precluding the possibil-
ity to assess clonality on them.
Treatment and Outcome
Among the 5 dogs, 4 underwent splenectomy and re-
ceived chemotherapy (doxorubicin as single agent)
thereafter, and 1 was splenectomized with no further
treatment. Three out of the 4 dogs treated with surgery
and adjuvant chemotherapy died of causes unrelated to
lymphoma, after 760, 939, and 1,825 days, whereas the
Fig 1. Histology of the spleen. Effacement of normal architecture
by coalescing nodules composed of a prevalence of marginal cells
and characterized by loss of mantle cells. Hematoxylin and eosin,
bar5 170mm.
Fig 2. Histology of the spleen. Coalescing areas of neoplastic cells
with abundant eosinophilic cytoplasm and complete loss of normal
splenic architecture, bar5 160mm.
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remaining dog was alive and in CR at the end of the
study, after 445 days.
The dog not receiving any adjuvant treatment experi-
enced tumor relapse after 180 days and was euthanized.
Relapse occurred in the peripheral LN(s) and was con-
ﬁrmed by means of cytology.
Discussion
MZL is a well-known clinicopathological entity in hu-
man medicine and clinical outcome mostly depends on
anatomical site of involvement.7 In veterinary medicine,
the recognition of MZL as a distinct disease has been re-
cent,1,3 therefore data on natural history and treatment
response have been limited. Our goal was to describe
clinical characteristics, treatment, and outcome of dogs
with splenic MZL, to understand whether they behave
like the indolent ones, as previously stated,3 or should be
considered as clinically aggressive. By deﬁnition, indo-
lent lymphomas grow slowly or remain stable for long
periods of time, and are histologically of low to interme-
diate grade. Indolent lymphomas are traditionally
moderately to fairly chemo- and radio-resistant; there-
fore a conservative treatment is usually suggested,
meaning metronomic strategy instead of a dose-intense
approach (aiming at administrating the chemotherapeu-
tic drugs as high as possible), to keep quality of life and
avoid unnecessary toxicity. If lymphoma is asymptomat-
ic, deferring treatment may represent an option.
MZL is the lymphoma type most frequently arising in
the spleen in both humans and dogs. Splenic MZL is
characterized by uniform involvement of follicular areas,
leading to generalized splenomegaly in human pa-
tients,8,9 which usually becomes symptomatic if massive
or if associated with peripheral cytopenias. BM and
blood are frequently involved (in up to 90% of cases)
without worsening prognosis.10 Because of the relatively
benign clinical course, treatment is required in selected
cases only, such as those exhibiting symptomatic spleno-
megaly and/or cytopenia, with splenectomy being the
treatment of choice.10,11 Follow-up chemotherapy
(mainly consisting of alkylating agents or purine ana-
logues) can play a role in the presence of poor prognostic
factors, positive staging work-up, ‘‘b’’ substage and/or
cytologic presence of large cells (420%).12
In our series of dogs, the hallmark of splenic MZL was
a focal hypoechoic mass, as previously described,3 which
only became symptomatic in case of rupture, leading to
secondary hemoabdomen. Early in the disease, splenic
MZL was identiﬁed accidentally during palpation. This
is in contrast with high-grade lymphomas, in which gen-
eralized splenomegaly, rather than an isolated mass, is
usually observed.13 Unlike human patients, in which BM
involvement is very common, in this series none of the
dogs had BM inﬁltration at presentation. Based on our
results, splenic MZL may have an indolent biologic be-
havior, and this is in agreement with a previous study.3
Diagnosis is usually made when dogs become symptom-
atic, as in case of splenic rupture, or by abdominal
ultrasound performed for other reasons. Here, treatment
of splenic MZL varied: 4 dogs underwent splenectomy
and adjuvant chemotherapy, whereas 1 dog underwent
surgery only. The 3 longest survivals were recorded in
dogs treated by means of surgery and adjuvant chemo-
therapy, possibly suggesting a beneﬁt for the combined
therapy. Lymphoma cases are usually treated pharmaco-
logically in dogs, and the role of splenectomy has been
limited to palliate clinical signs related to hypersplenism,
remove spleens at risk for rupture or eliminate the focus
of residual disease in dogs having successfully responded
to chemotherapy in other sites.14 Based on our results, we
hypothesize that surgery may also play an important role
in the management of splenic MZL, possibly improving
outcome. Whether adjuvant chemotherapy is necessary in
an adjuvant (postsurgical) setting has not been evaluated
before. Our ﬁndings suggest that systemic monochemo-
therapy can be useful in preventing relapse, possibly
eradicatingminimal residual disease. However, 3 dogs with
splenic MZL were alive between 7 and 19 months after
splenectomy only.3 This ﬁnding has important clinical
Fig 3. Histology of the spleen. High magniﬁcation of a nodule of
Figure 1 characterized by compression of residual splenic paren-
chyma by marginal zone expansion, bar5 45 mm.
Fig 4. Histology of the spleen. Substitution of a normal follicle by
a monomorphic population of cells with central round nucleus char-
acterized by chromatin peripheralization and evidence of a central
prominent nucleolus, bar5 25mm.
92 Stefanello et al
implication, as conservative (surgical) treatment could lead
to prolonged survival, thereby outlining the importance of
obtaining a deﬁnitive histological diagnosis before discuss-
ing prognosis with the owners. Indeed, the general
diagnosis of ‘‘lymphoma’’ is largely inaccurate, as differ-
ent types of lymphoma have different biological behavior
and harbor different prognosis, not necessarily being poor,
as demonstrated by this series of dogs.
The detection of clonality by means of molecular
methods may further improve the possibility to achieve
a deﬁnitive diagnosis. In our study, 3 out of 5 splenic
samples showed IgH clonal rearrangement, while on 2
cases no PCR products were detected. The lack of visible
immunoglobulin rearrangement, however, could be in-
terpreted as a false negative result. Indeed, as already
reported,15 there are several causes of PARR false nega-
tive results, such as exhibition of V- or J-region gene
segments not being ampliﬁed by the primers used and in-
adequate tissue quality for PCR analysis. This could
explain the negative results obtained in 2 samples, in
which the lymphoid neoplasm was histopathologically
conﬁrmed. The nucleic acid extracts from formalin-ﬁxed
tissues are not always suitable for ampliﬁcation, being
attributable to scarce or degraded DNA, or presence of
remnants of formalin or xylene, which contain inhibitors
of extraction procedures or ampliﬁcation reaction. Thus,
as already reported,3 the accurate interpretation of clon-
ality results requires histological tissue examination as
well as immunophenotyping.
This study has several limitations, including low num-
ber of cases and retrospective nature, which precluded to
have a homogeneous population in terms of treatment.
Furthermore, since histopathological evaluation was an
inclusion criteria, cases for which only cytology was
available were excluded.
In people, MZL arising from different anatomic sites
have different biologic behavior, with nodal lymphomas
having a more aggressive clinical course than splenic
ones, thereby requiring a more aggressive therapeutic
strategy.16 Future works should be aimed at evaluating if
the same holds true for dogs.
In conclusion, splenic MZL seems to be an indolent
disease and may beneﬁt from splenectomy, possibly fol-
lowed by systemic chemotherapy. Future clinical trials
should focus on the prognostic role of adjuvant chemo-
therapy. Best treatment options for this poorly described
disease remain to be deﬁned in dogs.
Footnotes
aRecoverAll Total Nucleic Acid Isolation Kit, Ambion, Austin, TX
bNanoDrop Technologies Inc, Wilmington, DE
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